AstraZeneca (AZN) Shares Down 0.5%

Galtero Lara
Diciembre 8, 2017

Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company's stock worth $454,000 after purchasing an additional 94 shares during the last quarter. Banque Pictet & Cie SA's holdings in AstraZeneca plc were worth $16,558,000 as of its most recent SEC filing.

A number of brokerages have commented on AZN. Meeder Asset Management Inc. bought a new stake in AstraZeneca in the second quarter worth about $105,000. Financial Counselors Inc. now owns 6,871 shares of the company's stock worth $234,000 after purchasing an additional 182 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its holdings in shares of AstraZeneca by 71.2% in the second quarter. Quadrant Capital Group LLC lifted its stake in AstraZeneca by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company's stock worth $147,000 after purchasing an additional 846 shares during the period. FTB Advisors Inc. grew its holdings in shares of AstraZeneca by 3.2% during the second quarter. Finally, First Interstate Bank increased its holdings in shares of AstraZeneca by 10.3% in the second quarter. The firm owned 269,557 shares of the company's stock after selling 5,520 shares during the period.

AstraZeneca (AZN) opened at GBX 4,704 ($63.31) on Monday. The stock has a market capitalization of $81,527.05, a price-to-earnings ratio of 7.68, a price-to-earnings-growth ratio of 3.12 and a beta of 0.72. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. AstraZeneca plc has a 1-year low of $25.55 and a 1-year high of $35.27.

More news: White US officer gets 20 years for killing black male

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. They expect $0.47 earnings per share, down 61.16% or $0.74 from last year's $1.21 per share. The business had revenue of $6.23 billion for the quarter, compared to analysts' expectations of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The firm's revenue for the quarter was down 11.6% on a year-over-year basis. S&P Research upgraded the shares of AZN in report on Friday, July 31 to "Buy" rating. The stock of AstraZeneca PLC (NYSE:AZN) earned "Hold" rating by HBSC on Monday, February 8.

AstraZeneca PLC (LON:AZN)'s share price dropped 0.5% on Monday. Cowen reaffirmed a "hold" rating and set a $37.00 price target on shares of AstraZeneca in a research note on Tuesday, October 17th. The company was initiated on Friday, September 9 by Deutsche Bank. Berenberg Bank restated a "buy" rating on shares of AstraZeneca plc in a research report on Tuesday, February 21st. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. AstraZeneca presently has a consensus rating of "Hold" and a consensus target price of $34.20. The short interest to Astrazeneca Plc's float is 0.6%. If you are accessing this article on another publication, it was illegally stolen and republished in violation of United States and global trademark and copyright legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/07/astrazeneca-plc-azn-shares-bought-by-oppenheimer-asset-management-inc.html. The Company's marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Want to see what other hedge funds are holding AZN?

Otros informes por

Discuta este artículo

SIGUE NUESTRO PERIÓDICO